A novel immunotherapy approach developed by researchers at MIT and Stanford University is offering a potential breakthrough in the fight against cancer. The study, published in *Nature Biotechnology*, details a strategy to bypass tumor defenses by targeting glycans – sugar molecules on the surface of cancer cells – and could broaden the effectiveness of immunotherapy for patients who haven’t responded to existing treatments[3]. This research represents a meaningful step toward overcoming one of the biggest challenges in oncology: enabling the immune system to recognize and destroy previously “hidden” tumors.
A groundbreaking immunotherapy strategy developed by scientists at MIT and Stanford University could represent a turning point in modern cancer treatment. The new approach offers a different way to activate the immune system to identify and destroy tumor cells more effectively, even in patients who don’t respond to currently available therapies.
This research aims to broaden the reach of immunotherapy, a cancer treatment that harnesses the body’s own defenses, and overcome a major challenge in oncology: the ability of tumors to hide from the immune system. Immunotherapy has shown promise in treating various cancers, but its effectiveness is limited by the tumor’s ability to evade detection.
The study’s findings were published in the journal Nature Biotechnology and led by Jessica Stark, a researcher at MIT, and Carolyn Bertozzi, of Stanford. The work provides new insights into how tumors manipulate the immune system and how that manipulation can be neutralized.
The Hidden Role of Glycans in Tumor Evasion
For years, immunotherapy has focused on releasing known immune “brakes,” such as PD-1 and PD-L1 checkpoints. While these treatments have led to prolonged remission in some patients, they haven’t worked for many others. Researchers now believe cancer utilizes multiple mechanisms to disable the body’s defenses.
One significant mechanism involves glycans, sugar molecules that coat the surface of cancer cells. These glycans, particularly those containing sialic acid, interact with immune receptors called Siglecs, found on key immune cells.
This interaction sends a “do not attack” signal to the immune cells, effectively allowing the tumor to disguise itself as healthy tissue and grow undetected. This mechanism is similar to other immune checkpoints, but until now, there haven’t been therapies approved to effectively and selectively block it.
Genetic therapy reduces cholesterol by half
AbLecs: Hybrid Proteins That Release the Immune Brake
To address this, the scientists designed hybrid proteins called AbLecs, which combine two key elements: a highly specific antibody that recognizes cancer cells and a lectin capable of strongly binding to tumor glycans.
This strategic combination allows the lectin to be delivered directly to the tumor surface, something that wasn’t possible when the lectin was used alone. Once there, the lectin blocks the glycans and deactivates the immune brake based on Siglecs, reactivating the defensive response.
According to Jessica Stark, these proteins function as a new type of immune checkpoint inhibitor, but one focused on glycans. The result is a more intense and precise immune response, particularly from macrophages and NK cells, two key players in eliminating cancer cells.
In laboratory experiments, AbLecs reprogrammed immune cells to destroy tumors more efficiently than conventional antibodies.
Scientists discover how to prevent Alzheimer’s from erasing faces
Promising Results and Personalized Therapies
Animal studies further reinforced the potential of this strategy. In mice with lung metastases, treatment with AbLecs reduced cancer spread more significantly than a traditional antibody used alone.
Another key aspect of the discovery is its modular nature. Researchers can change both the antibody and the lectin depending on the type of cancer and the specific mechanism it uses to evade the immune system. This opens the door to personalized cancer therapies, tailored to each tumor.
With over 20,000,000 new cancer cases diagnosed worldwide each year, according to international data, this flexibility represents a significant strategic advantage. This isn’t just a new drug, but an adaptable platform that could be integrated with existing treatments.
Although clinical trials in humans are still needed, scientists believe this research lays the foundation for a new generation of immunotherapies. By targeting a previously unexplored immune brake, the approach could benefit patients who currently have limited effective options.
Subscribe to the magazine and register for our newsletters to receive the best content in your inbox.
